EN
Sinovac Beijing's QC Laboratory Accredited By CNAS
August 20, 2022, Beijing – Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Quality Control (QC) laboratory of its subsidiary Sinovac Beijing, has been accredited by the China National Accreditation Service for Conformity Assessment (CNAS), confirming the lab meets ISO 17025 global standards for operational competence and validity.
The certification (Registration No. CNAS L16860) is in accordance with ISO/IEC 17025 requirements for testing and calibration laboratories. The accreditation signals the Beijing Sinovac QC laboratory meets global industry regulations for quality and accuracy for 50 total parameters, to competently undertake services for six types of testing objects for biological products, prefilled syringe assembly and more.
In conferring the accreditation, CNAS' review committee assessed the QC laboratory's quality management system and testing capabilities for biological products and packaging materials. The committee unanimously certified the high standards of the laboratory's environmental conditions, organizational structure, personnel, equipment and operations of its quality management system. The committee confirmed that the QC laboratory met all application parameters.
About CNAS
The China National Accreditation Service for Conformity Assessment (CNAS) is China's national accreditation body unitarily responsible for the accreditation of certification bodies, laboratories and inspection bodies, established under the approval of the Certification and Accreditation Administration of the People's Republic of China (CNCA) and authorized in accordance with the Regulations of the People's Republic of China on Certification and Accreditation.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.